Ensysce Biosciences Q4 2025 Earnings Report

Ensysce Biosciences EPS Results

• Actual EPS: -$0.75
• Consensus EPS: -$1.26
• Beat/Miss: Beat by +$0.51
• One Year Ago EPS: N/A

Ensysce Biosciences Revenue Results

• Actual Revenue: $1.88 million
• Expected Revenue: $0.50 million
• Beat/Miss: Beat by +$1.38 million
• YoY Revenue Growth: N/A

Ensysce Biosciences Announcement Details

• Quarter: Q4 2025
• Date: 3/30/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Ensysce Biosciences (NASDAQ:ENSC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations. Ensysce is advancing ENS100 through preclinical studies and regulatory interactions, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Beyond pain management, the platform underpins additional pipeline programs targeting other central nervous system indications where controlled drug delivery may enhance therapeutic benefit and safety.

Founded with a mission to address critical public health challenges, Ensysce Biosciences operates primarily in the United States and engages in collaborative partnerships to support its research and development activities. The company holds a portfolio of issued patents and pending applications covering its enzyme-activated prodrug technologies, reflecting a commitment to innovation in the design of safer pharmaceutical therapies.